FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND

Comments
Loading...
  • The FDA has lifted the clinical hold on Immunome Inc's IMNM Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19. 
  • Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for further information related to the preparation and administration of IMM-BCP-01 at clinical sites. 
  • In response, Immunome provided the FDA with a comprehensive report detailing the necessary information.
  • Related: Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus.
  • "We believe in the potential of IMM-BCP-01 and its ability to aid in the ongoing fight against SARS-CoV-2, especially as the new variants continue," said Purnanand Sarma, President & CEO of Immunome. "We are pleased to report that the clinical hold has now been lifted. We look forward to advancing the program into the clinic.
  • Price Action: IMNM shares are down 6.56% at $3.99 during the market session on the last check Friday.
IMNM Logo
IMNMImmunome Inc
$8.73-1.36%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum7.50
Growth-
Quality-
Value8.73
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: